| Q22306358 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q44497625 | A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure |
| Q33985849 | A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment |
| Q37390747 | Anemia and chronic heart failure: from pathophysiologic mechanisms to clinical trial designs |
| Q45291209 | Anemia and early mortality in patients with decompensation of chronic heart failure |
| Q38039849 | Anemia and iron deficiency in heart failure |
| Q37883005 | Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches |
| Q37258782 | Anemia and the potential role of erythropoiesis-stimulating agents in heart failure |
| Q36600453 | Anemia associated with chronic heart failure: current concepts |
| Q48181091 | Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome |
| Q37943240 | Anemia in chronic heart failure: can we treat? What to treat? |
| Q37822727 | Anemia in heart failure: an overview of current concepts |
| Q37445907 | Anemia in heart failure: pathophysiologic insights and treatment options |
| Q50627745 | Anemia in heart failure: to treat or not to treat? |
| Q91142603 | Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial |
| Q27012659 | Anemia, heart failure and evidence-based clinical management |
| Q84120974 | Anemia: What can we learn from a secondary analysis of CHOIR? |
| Q37130139 | Approaches to the treatment of anaemia in patients with chronic heart failure |
| Q36423854 | Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study |
| Q38380236 | Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial |
| Q34564073 | Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data |
| Q36623051 | Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). |
| Q38068097 | Cardiorenal syndrome: pathophysiology and potential targets for clinical management |
| Q37696360 | Cardiorenal syndrome: still not a defined entity |
| Q37533151 | Cardiovascular Effects of Erythropoietin |
| Q30435143 | Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction |
| Q37880858 | Chronic heart failure: current evidence, challenges to therapy, and future directions |
| Q37804571 | Chronic kidney disease and heart failure—Bidirectional close link and common therapeutic goal |
| Q34118880 | Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial |
| Q36973213 | Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions |
| Q37008467 | Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways |
| Q37038709 | Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure |
| Q34479931 | Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial |
| Q50602023 | Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. |
| Q37330335 | Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the heart failure with preserved ejection fraction (HFPEF) anemia trial |
| Q38199991 | Distinguishing anemia and iron deficiency of heart failure: signal for severity of disease or unmet therapeutic need? |
| Q37956569 | Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review |
| Q41016380 | Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis |
| Q37802925 | Erythropoiesis-stimulating agents and heart failure |
| Q24241045 | Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients |
| Q37098040 | Erythropoietic agents and the elderly |
| Q43749166 | Erythropoietin and heart failure: the end of a promise? |
| Q35091635 | Erythropoietin and organ protection: lessons from negative clinical trials |
| Q37798565 | Erythropoietin and the heart: facts and perspectives. |
| Q37952603 | Erythropoietin: a future therapy for failing hearts? |
| Q39977624 | Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients |
| Q39419921 | Heart failure and iron deficiency anemia in Italy: results from CARMES-1 registry |
| Q38182010 | Heart failure highlights in 2012-2013. |
| Q37762930 | Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. |
| Q94554217 | Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials |
| Q89071688 | Iron Therapy in Heart Failure: Ready for Primetime? |
| Q37790519 | Iron deficiency and anaemia in heart failure: understanding the FAIR-HF trial. |
| Q38551016 | Iron deficiency and cardiovascular disease |
| Q36682182 | Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives |
| Q48306942 | Iron in kidney and heart failure: from theory to practice |
| Q28088503 | Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? |
| Q37661050 | Is there a role for erythropoietin in cardiovascular disease? |
| Q41686228 | Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. |
| Q50893143 | Long term effects of epoetin alfa in patients with ST- elevation myocardial infarction. |
| Q42824239 | Management of Anemia and Iron Deficiency in Heart Failure |
| Q38537053 | Management of Noncardiac Comorbidities in Chronic Heart Failure |
| Q33797640 | Managing anemia in patients with chronic heart failure: what do we know? |
| Q37604882 | Mechanisms of the cardiorenal syndromes |
| Q37880500 | Narrative review: the management of acute decompensated heart failure |
| Q37531314 | Noncardiac comorbidities and acute heart failure patients. |
| Q37437162 | Novel pharmacotherapies to abrogate postinfarction ventricular remodeling |
| Q47954573 | Optimal hematocrit in an artificial microvascular network |
| Q37552943 | Overview of emerging pharmacotherapy in chronic heart failure |
| Q37812022 | Pathogenesis and therapeutic implications of cardiorenal syndrome |
| Q39660099 | Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists? |
| Q39740830 | Pharmacological management of cardiorenal syndromes |
| Q37390743 | Prevalence of anemia in heart failure and its effects on prognosis |
| Q33433326 | Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial |
| Q30952502 | Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis |
| Q40776947 | Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure |
| Q42753015 | Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia |
| Q50524585 | Red blood cell transfusions in children awaiting heart transplantation. |
| Q37653905 | Relationship between anemia and health care costs in heart failure |
| Q50482182 | The Role of Treatment for Anemia as a Therapeutic Target in the Management of Chronic Heart Failure: Insights After RED-HF. |
| Q34987168 | The causes, consequences, and treatment of left or right heart failure |
| Q37231779 | The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions |
| Q30475623 | The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction |
| Q30883735 | The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study |
| Q34679370 | The optimum hematocrit |
| Q37243581 | The role of correction of anaemia in patients with congestive heart failure: a short review |
| Q37791923 | The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome |
| Q34065957 | The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions |
| Q57422687 | The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure |
| Q38226494 | Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure |
| Q43480625 | Use of novel and conventional biomarkers for management of patients with heart failure |
| Q83800994 | Vitamin D deficiency is an independent predictor of anemia in end-stage heart failure |
| Q52821448 | [Acute and chronic heart failure]. |
| Q83250047 | [Advances in heart failure] |
| Q83179007 | [Update on geriatric cardiology] |
Search more.